|MDACC Study No:||2013-0036 (clinicaltrials.gov NCT No: NCT01696045)|
|Title:||A Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 years) with|
Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant
|Principal Investigator:||Cynthia E. Herzog|
|Study Description:||The goal of this clinical research study is to learn if Yervoy™ (ipilimumab) |
can help to control metastatic melanoma. The safety of this drug will also be
Ipilimumab is designed to increase the immune system's ability to fight cancer.
The drug blocks a molecule that is believed to shut down the part of the immune
system that attacks cancer cells.